The S-oxidation of S-carboxymethyl-L-cysteine in hepatic cytosolic fractions from BTBR and phenylketonuria enu1 and enu2 mice

Abstract

1. Mice that were heterozygous dominant for the enu1 and enu2 mutation in phenylalanine monooxygenase/phenylalanine hydroxylase (PAH) resulted in hepatic PAH assays for S-carboxymethyl-L-cysteine (SCMC) that had significantly increased calculated K_m (wild type (wt)/enu1, 1.84–2.12 fold increase and wt/enu2 a 2.75 fold increase in PAH assays). The heterozygous dominant phenotypes showed a significantly reduced catalytic turnover of SCMC (wt/enu1, 6.11 fold decrease and wt/enu2 an 11.25 fold decrease in calculated V_max). Finally, these phenotypes also had a significantly reduced clearance, C_LE (wt/enu1, 13.02 fold and wt/enu2, a 30.80–30.94 fold decrease) The homozygous recessive phenotype (enu1/enu1) was also found to have significantly increased calculated K_m (2.16 fold increase), a significantly reduced calculated V_max (11.35–12.33 fold decrease) and C_LE (24.75–25.00 fold decrease). The enu2/enu2, homozygous recessive phenotype had no detectable PAH activity using SCMC as substrate.

2. The identity of the enzyme responsible for the C-oxidation of L-phenylalanine (L-Phe) and the S-oxidation of SCMC in wt/wt (BTBR) mice was identified using monoclonal antibody and selective chemical inhibitors and was found to be PAH.

3. This in vitro mouse hepatic cytosolic fraction metabolism investigation provides further evidence to support the hypothesis that an individual possessing one variant allele for PAH will result in a poor metaboliser phenotype that is unable to produce significant amounts of S-oxide metabolites of SCMC.

Keywords:

• S-carboxymethyl-L-cysteine
• phenylketonuria model mice
• S-oxidation
• enzyme kinetics